Collaborative efforts between pediatric and adult oncologists are helping shape a bright future for adult and young adult (AYA) patients with Hodgkin and non-Hodgkin lymphoma alike. In this final installment of his interview with The American Journal of Managed Care® […]
Collaboration Advances Lymphoma Care: Andrew Evens, DO Read More »
US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas
Striving for Health Equity: Antoine Keller, MD Read More »
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD Read More »
The 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference held in Dallas, Texas, marked the 75th anniversary of the MDA. As clinicians harkened back to the most valuable elements of the meeting, they highlighted the great collaborative opportunities that
Building Community and Advancing Care at MDA 2025 Read More »
Lipoprotein(a) (Lp[a]) levels can lead to plaque build-up in the arteries and, as such, be a notable risk marker for a myriad of cardiovascular issues. Ahead of Lp(a) Awareness on March 24, Nathan Wong, PhD, FACC, FAHA, FNLA, director, University
Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches Read More »
The FDA has approved vutrisiran (Amvuttra; Alnylam Pharmaceuticals) for adult patients with cardiomyopathy classified as either hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type. With this announcement, vutrisiran becomes the only approved RNA interference (RNAi) intervention to mitigate cardiovascular-related hospitalizations and deaths,
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions Read More »
The advent of chimeric antigen receptor (CAR) T-cell therapies has brought numerous advantages to the multiple myeloma treatment landscape; however, implementing these therapies into clinical practice comes with its own challenges. In this interview with The American Journal of Managed
The Pragmatic Trial of Messaging to Providers (PROMPT) Trials are a series of randomized studies that focus on implementing electronic medical-based alerts to enhance patients outcomes and overall care. At present, these trials are grouped into 4 divisions: lipids, heart
PROMPT Trials, Electronic Alerts, and Enhancing CV Outcomes Read More »
Addressing the cost of gene therapies has remained a prominent challenge as these interventions have become available for patients with spinal muscular atrophy, Duchenne muscular dystrophy (DMD), and other neuromuscular diseases. In this interview, Leigh Maria Ramos-Platt, MD, Children’s Hospital
Equitable Health Care Access Extends Beyond Costs, Medications Read More »
Biomarker exploration has been a crucial component of amyotrophic lateral sclerosis (ALS), explained Tania Gendron, PhD, assistant professor of neuroscience, Mayo Clinic. Data at the individual level has been lacking, Gendron noted, which creates additional challenges in patient care that
